退伍军人长期照护机构中抗胆碱能药物使用模式与减药机会
该研究基于2007-2019财年VA社区生活中心≥65岁长住退伍军人(N=45,183)的条形码给药记录进行二次分析,发现33.4%使用抗胆碱能药物。痴呆居民中第二代抗精神病药(30.6%)和抗帕金森药(10.1%)暴露突出,第一代抗组胺药仍达29.5%;非痴呆居民以抗组胺药(34.4%)和膀胱抗毒蕈碱药(23.7%)为主。总体使用呈小幅下降,提示第一代抗组胺药等可干预暴露来源需关注减药。
要点
- 33.4%的VA社区生活中心长住退伍军人使用抗胆碱能药物。
- 痴呆居民中第二代抗精神病药暴露达30.6%,第一代抗组胺药达29.5%。
- 非痴呆居民中抗组胺药(34.4%)和膀胱抗毒蕈碱药(23.7%)较常见。
核心结论
- 部分抗胆碱能药物类别可能临床必需,但第一代抗组胺药等暴露来源可能被低估且可干预,需推动减药。
研究设计与样本
- 基于VA社区生活中心2007-2019财年≥65岁、住院≥90天退伍军人(N=45,183)的二次数据分析,使用条形码给药记录测量抗胆碱能暴露,随访至出院、死亡或2025年4月1日。
主要发现
- 45,183名居民中33.4%(n=15,074)使用抗胆碱能药物。
- 痴呆居民(n=20,254)中第二代抗精神病药使用30.6%、抗帕金森药10.1%、第一代抗组胺药29.5%。
- 非痴呆居民(n=24,929)中抗组胺药34.4%、膀胱抗毒蕈碱药23.7%、骨骼肌松弛剂11.1%。
- 2007-2019财年抗胆碱能药物使用小幅下降:抗组胺药12.1%→8.8%,抗抑郁药6.8%→3.5%,止吐/抗眩晕药5.2%→1.2%。
- 使用单一抗胆碱能类别的居民比例从75.5%升至82.2%。
关键数值与推荐
- 抗胆碱能药物使用定义为在CLC住院期间每周使用≥4天。
- 药物识别采用与2023年美国老年医学会Beers标准一致的VA分类,分为九个抗胆碱能类别。
临床怎么用
- 对长期照护机构老年居民应系统审查抗胆碱能负荷,尤其关注第一代抗组胺药等非处方来源。
- 痴呆居民需重点评估第二代抗精神病药和抗帕金森药的抗胆碱能暴露,结合临床必要性考虑减药。
- 非痴呆居民应关注抗组胺药、膀胱抗毒蕈碱药和骨骼肌松弛剂的抗胆碱能风险,推动处方优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anticholinergic exposure is common in nursing homes; however, the true burden may be underestimated, particularly due to over-the-counter agents such as first-generation antihistamines that are not consistently captured in prior claims-based studies. This gap limits accurate characterization of anticholinergic use and its clinical implications in older adults. PARTICIPANTS AND SETTING: Veterans aged ≥ 65 years with stays ≥ 90 days (N = 45,183) residing in US Department of Veterans Affairs (VA) Community Living Centers (CLC). This study is a secondary data analysis of residents identified during fiscal years 2007-2019. METHODS: True anticholinergic exposure through barcode-based medication administration dispensing records allowed daily measurement of anticholinergic exposure, with follow-up extending from admission to discharge, death, or April 1, 2025. Anticholinergic medication use was defined as use ≥ 4 days per week during the CLC stay. Drugs were identified using VA classifications aligned with the 2023 American Geriatrics Society Beers Criteria and grouped into nine anticholinergic classes. Outcomes included prevalence, duration, and number of anticholinergic drug classes used; patterns by dementia status; and temporal trends over time. RESULTS: Among 45,183 CLC residents, 33.4% (n = 15,074) used anticholinergic medications. Residents with dementia (n = 20,254) showed substantial exposure to neuropsychiatric anticholinergics, including second-generation antipsychotics (30.6%) and antiparkinsonian agents (10.1%). First-generation antihistamine use remained high in this group (29.5%). Residents without dementia (n = 24,929) more frequently received antihistamines (34.4%), bladder antimuscarinics (23.7%), and skeletal muscle relaxants (11.1%). From FY2007-2019, anticholinergic use declined modestly, with decreases in antihistamines (12.1%-8.8%), antidepressants (6.8%-3.5%), and antiemetic/antivertigo agents (5.2%-1.2%). Most residents used a single anticholinergic class, increasing from 75.5% to 82.2% over time. CONCLUSIONS: Although some anticholinergic classes may be clinically necessary, our findings highlight potentially underrecognized and modifiable sources of exposure, particularly first-generation antihistamines, underscoring the need for deprescribing efforts.
引用
- Hayes CA, Li Y, Jing B, et al. Anticholinergic Medication Use in Veterans Affairs Long-Term Care Residents: Clinical Patterns and Opportunities for Deprescribing. J Am Geriatr Soc. 2026. PMID: 42378629. doi:10.1111/jgs.70570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。